News articles about Enzymotec (NASDAQ:ENZY) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzymotec earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.302532929143 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Enzymotec (NASDAQ ENZY) remained flat at $$11.85 during midday trading on Friday. Enzymotec has a 12 month low of $6.30 and a 12 month high of $12.35. The company has a market cap of $277.62, a P/E ratio of -43.89, a P/E/G ratio of 3.19 and a beta of 1.22.
ENZY has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Jefferies Group reiterated a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research note on Thursday, October 19th. Wells Fargo & Co raised their price objective on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. Finally, BidaskClub lowered shares of Enzymotec from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. Enzymotec currently has an average rating of “Hold” and an average target price of $11.75.
ILLEGAL ACTIVITY NOTICE: “Enzymotec (ENZY) Given Daily News Impact Rating of 0.23” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/13/enzymotec-enzy-given-daily-news-impact-rating-of-0-23.html.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.